Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
By focusing on several pathways related to energy expenditure, glucose metabolism, and appetite management, these new medications aim to improve efficacy, tolerability, and metabolic advantages
Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores
GLP-1 agonists can effectively help lower blood sugar levels, while posing a low risk of hypoglycaemia when used on their own, unlike some other classes of medications
monoclonal antibody manufacturing) into GLP-1 programs, driving up labor costs
US$ 27.79
US$ 20.42
US$ 28.95
US$ 26.15
